• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

辐射通过激活 NF-κB/Icam1 信号增强 EGFR 靶向 CAR-T 细胞对三阴性乳腺癌的疗效。

Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling.

机构信息

State Key Laboratory of Oncogenes & Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China.

State Key Laboratory of Oncogenes & Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China.

出版信息

Mol Ther. 2022 Nov 2;30(11):3379-3393. doi: 10.1016/j.ymthe.2022.07.021. Epub 2022 Aug 4.

DOI:10.1016/j.ymthe.2022.07.021
PMID:35927951
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9637637/
Abstract

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, with limited treatment options. Epidermal growth factor receptor (EGFR) is reported to be expressed in 50%-75% of TNBC patients, making it a promising target for cancer treatment. Here we show that EGFR-targeted chimeric antigen receptor (CAR) T cell therapy combined with radiotherapy provides enhanced antitumor efficacy in immunocompetent and immunodeficient orthotopic TNBC mice. Intriguingly, this combination therapy resulted in a substantial increase in the number of tumor-infiltrating CAR-T cells. The efficacy of this combination was independent of tumor radiosensitivity and lymphodepleting preconditioning. Cytokine profiling showed that this combination did not increase the risk of cytokine release syndrome (CRS). RNA sequencing (RNA-seq) analysis revealed that EGFR-targeting CAR-T therapy combined with radiotherapy increased the infiltration of CD8 T and natural killer (NK) cells into tumors. Mechanistically, radiation significantly increased Icam1 expression on TNBC cells via activating nuclear factor κB (NF-κB) signaling, thereby promoting CAR-T cell infiltration and killing. These results suggest that CAR-T therapy combined with radiotherapy may be a promising strategy for TNBC treatment.

摘要

三阴性乳腺癌(TNBC)是最具侵袭性的乳腺癌亚型,治疗选择有限。据报道,表皮生长因子受体(EGFR)在 50%-75%的 TNBC 患者中表达,使其成为癌症治疗的有前途的靶点。在这里,我们表明 EGFR 靶向嵌合抗原受体(CAR)T 细胞疗法联合放射治疗在免疫功能正常和免疫缺陷的原位 TNBC 小鼠中提供了增强的抗肿瘤疗效。有趣的是,这种联合治疗导致肿瘤浸润的 CAR-T 细胞数量大量增加。这种联合治疗的疗效与肿瘤放射敏感性和淋巴耗竭预处理无关。细胞因子分析表明,这种联合治疗不会增加细胞因子释放综合征(CRS)的风险。RNA 测序(RNA-seq)分析显示,EGFR 靶向 CAR-T 疗法联合放射治疗增加了 CD8 T 和自然杀伤(NK)细胞浸润肿瘤。从机制上讲,辐射通过激活核因子κB(NF-κB)信号显著增加 TNBC 细胞上的 Icam1 表达,从而促进 CAR-T 细胞浸润和杀伤。这些结果表明,CAR-T 疗法联合放射治疗可能是治疗 TNBC 的一种有前途的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d289/9637637/390404e72484/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d289/9637637/390404e72484/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d289/9637637/390404e72484/fx1.jpg

相似文献

1
Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling.辐射通过激活 NF-κB/Icam1 信号增强 EGFR 靶向 CAR-T 细胞对三阴性乳腺癌的疗效。
Mol Ther. 2022 Nov 2;30(11):3379-3393. doi: 10.1016/j.ymthe.2022.07.021. Epub 2022 Aug 4.
2
Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.细胞间黏附分子-1 作为三阴性乳腺癌 CAR-T 细胞治疗的靶点。
Front Immunol. 2020 Sep 23;11:573823. doi: 10.3389/fimmu.2020.573823. eCollection 2020.
3
Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.利用表达特异性嵌合抗原受体的自然杀伤细胞靶向表皮生长因子过表达的三阴性乳腺癌。
Cell Prolif. 2020 Aug;53(8):e12858. doi: 10.1111/cpr.12858. Epub 2020 Jun 27.
4
Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition.针对三阴性乳腺癌的 EGFR CAR T 细胞与 CDK7 抑制联合疗法。
Cancer Immunol Res. 2021 Jun;9(6):707-722. doi: 10.1158/2326-6066.CIR-20-0405. Epub 2021 Apr 19.
5
EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC.表皮生长因子受体(EGFR)特异性嵌合抗原受体T细胞(CAR-T细胞)在EGFR阳性三阴性乳腺癌(TNBC)中引发细胞裂解。
Aging (Albany NY). 2019 Dec 4;11(23):11054-11072. doi: 10.18632/aging.102510.
6
EGFR as a potent CAR T target in triple negative breast cancer brain metastases.表皮生长因子受体作为三阴性乳腺癌脑转移的有效嵌合抗原受体 T 靶点。
Breast Cancer Res Treat. 2023 Jan;197(1):57-69. doi: 10.1007/s10549-022-06783-1. Epub 2022 Nov 1.
7
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.诱导性局部递送抗 PD-1 scFv 增强了 ROR1 CAR-T 细胞在三阴性乳腺癌中的抗肿瘤活性。
Breast Cancer Res. 2022 Jun 3;24(1):39. doi: 10.1186/s13058-022-01531-1.
8
Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.新型抗体药物偶联物针对 EGFR 阳性三阴性乳腺癌的优异疗效及可能作用机制。
Mil Med Res. 2021 Dec 9;8(1):63. doi: 10.1186/s40779-021-00358-9.
9
Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers.靶向跨膜肿瘤坏死因子 α 的 CAR-T 细胞与 PD-1 mAb 联合对乳腺癌的抗肿瘤作用。
J Immunother Cancer. 2023 Jan;11(1). doi: 10.1136/jitc-2021-003837.
10
EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both and .表皮生长因子受体(EGFR)靶向嵌合抗原受体(CAR)修饰的T细胞在体内和体外均能有效且特异性地抑制三阴性乳腺癌。
Clin Transl Immunology. 2020 May 3;9(5):e01135. doi: 10.1002/cti2.1135. eCollection 2020 May.

引用本文的文献

1
Nanoparticle technologies in precision oncology and personalized vaccine development: Challenges and advances.精准肿瘤学和个性化疫苗开发中的纳米颗粒技术:挑战与进展
Int J Pharm X. 2025 Jul 5;10:100353. doi: 10.1016/j.ijpx.2025.100353. eCollection 2025 Dec.
2
Exosomal CMTM4 Induces Immunosuppressive Macrophages to Promote Ovarian Cancer Progression and Attenuate Anti-PD-1 Immunotherapy.外泌体CMTM4诱导免疫抑制性巨噬细胞促进卵巢癌进展并削弱抗PD-1免疫治疗。
Adv Sci (Weinh). 2025 May 28:e04436. doi: 10.1002/advs.202504436.
3
Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy.

本文引用的文献

1
The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL).自然杀伤细胞免疫疗法治疗 B 细胞非霍奇金淋巴瘤(B 细胞 NHL)的未来。
Curr Treat Options Oncol. 2022 Mar;23(3):381-403. doi: 10.1007/s11864-021-00932-2. Epub 2022 Mar 8.
2
CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1.嵌合抗原受体(CAR)T细胞进入肿瘤胰岛是一个依赖于干扰素γ(IFNγ)和细胞间黏附分子-1(ICAM-1)的两步过程。
Cancer Immunol Res. 2021 Dec;9(12):1425-1438. doi: 10.1158/2326-6066.CIR-20-0837. Epub 2021 Oct 22.
3
Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
重编程乳腺肿瘤免疫微环境:从冷到热的转变以增强免疫治疗
J Exp Clin Cancer Res. 2025 Apr 25;44(1):131. doi: 10.1186/s13046-025-03394-8.
4
Recent advances in biomimetic nanodelivery systems for cancer Immunotherapy.用于癌症免疫治疗的仿生纳米递送系统的最新进展。
Mater Today Bio. 2025 Apr 5;32:101726. doi: 10.1016/j.mtbio.2025.101726. eCollection 2025 Jun.
5
Tumor Microenvironment Dynamics of Triple-Negative Breast Cancer Under Radiation Therapy.三阴性乳腺癌在放射治疗下的肿瘤微环境动态变化
Int J Mol Sci. 2025 Mar 20;26(6):2795. doi: 10.3390/ijms26062795.
6
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells.B7-H3嵌合抗原受体T细胞(CAR-T)疗法联合放射治疗可有效靶向原发性和耐放射的脊索瘤癌细胞。
J Immunother Cancer. 2025 Jan 22;13(1):e009544. doi: 10.1136/jitc-2024-009544.
7
ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis.ICOS 表达的 CAR-T 细胞介导三阴性乳腺癌及其转移灶的持久消除。
J Immunother Cancer. 2024 Nov 11;12(11):e010028. doi: 10.1136/jitc-2024-010028.
8
Radiation drives tertiary lymphoid structures to reshape TME for synergized antitumour immunity.辐射驱动三级淋巴结构重塑肿瘤微环境以实现协同抗肿瘤免疫。
Expert Rev Mol Med. 2024 Oct 23;26:e30. doi: 10.1017/erm.2024.27.
9
CAR-T cell therapy: Advances in digestive system malignant tumors.嵌合抗原受体T细胞疗法:消化系统恶性肿瘤的研究进展
Mol Ther Oncol. 2024 Sep 10;32(4):200872. doi: 10.1016/j.omton.2024.200872. eCollection 2024 Dec 19.
10
A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023.2012 年至 2023 年嵌合抗原受体 T 细胞治疗血液系统恶性肿瘤的文献计量学和知识图谱研究。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2371664. doi: 10.1080/21645515.2024.2371664. Epub 2024 Jul 3.
利用 CRISPR/Cas9 技术加强 CAR-T 细胞治疗应用。
Biotechnol Bioeng. 2021 Oct;118(10):3691-3705. doi: 10.1002/bit.27882. Epub 2021 Jul 21.
4
Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells.靶向 B7-H3 CAR T 细胞治疗辐射抵抗性前列腺癌干细胞。
Mol Cancer Ther. 2021 Mar;20(3):577-588. doi: 10.1158/1535-7163.MCT-20-0446.
5
Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.GD2-B7H3 SynNotch CAR-T 在转移性神经母细胞瘤中的疗效和特异性的临床前评估。
Nat Commun. 2021 Jan 21;12(1):511. doi: 10.1038/s41467-020-20785-x.
6
Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice.奥拉帕利通过 SDF1α/CXCR4 轴抑制 MDSC 募集,以提高 CAR-T 细胞对乳腺癌在小鼠中的抗肿瘤疗效。
Mol Ther. 2021 Jan 6;29(1):60-74. doi: 10.1016/j.ymthe.2020.09.034. Epub 2020 Sep 26.
7
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?嵌合抗原受体 T 细胞疗法治疗实体瘤:光明的未来还是黑暗的现实?
Mol Ther. 2020 Nov 4;28(11):2320-2339. doi: 10.1016/j.ymthe.2020.09.015. Epub 2020 Sep 16.
8
Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion.IL7 和 CCL21 的共表达可提高 CAR-T 细胞在实体瘤中的疗效,而无需预先进行淋巴清除。
Clin Cancer Res. 2020 Oct 15;26(20):5494-5505. doi: 10.1158/1078-0432.CCR-20-0777. Epub 2020 Aug 14.
9
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer.靶向赖氨酰氧化酶(LOX)克服三阴性乳腺癌的化疗耐药性。
Nat Commun. 2020 May 15;11(1):2416. doi: 10.1038/s41467-020-16199-4.
10
Breast cancer statistics, 2019.乳腺癌统计数据,2019 年。
CA Cancer J Clin. 2019 Nov;69(6):438-451. doi: 10.3322/caac.21583. Epub 2019 Oct 2.